Skip to main content
Premium Trial:

Request an Annual Quote

Life Technologies and SG Biofuels Sequence Jatropha Genome on SOLiD 4


This article was originally published Aug. 25.

Life Technologies and bioenergy crop firm SG Biofuels have sequenced the genome of Jatropha curcas, an oilseed plant, using the SOLiD 4.0 platform, the companies said last week.

The partners sequenced the 400-megabase jatropha genome to 100x coverage and are planning to generate a high-quality jatropha reference genome. They will also compare the genome to sequences generated from SG Biofuels' germplasm library of more than 6,000 unique jatropha genotypes in order to identify molecular markers and trait genes that can accelerate the development of new variants with better yields.

"Working with SG Biofuels to sequence the jatropha genome is an important part of our broader synthetic biology strategy to provide technologies for the development of next-generation renewable energy," said Wendy Jozsi, director of synthetic biology at Life Technologies, in a statement.

The companies are not the first to sequence jatropha: Last year, Synthetic Genomics and the Asiatic Centre for Genome Technology, a subsidiary of a Malaysian oil palm plantation company, said they completed a first draft of the jatropha genome, using a combination of Sanger capillary sequencing and 454 sequencing (IS 5/26/2009). Sequencing for that project was provided by the J. Craig Venter Institute.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.